These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 22005473)

  • 1. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
    Laurie SA; Gupta A; Chu Q; Lee CW; Morzycki W; Feld R; Foo AH; Seely J; Goffin JR; Laberge F; Murray N; Rao S; Nicholas G; Laskin J; Reiman T; Sauciuc D; Seymour L
    J Thorac Oncol; 2011 Nov; 6(11):1950-4. PubMed ID: 22005473
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase II study of intermittent sunitinib malate as second-line therapy in progressive malignant pleural mesothelioma.
    Nowak AK; Millward MJ; Creaney J; Francis RJ; Dick IM; Hasani A; van der Schaaf A; Segal A; Musk AW; Byrne MJ
    J Thorac Oncol; 2012 Sep; 7(9):1449-56. PubMed ID: 22895142
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group.
    Laurie SA; Hao D; Leighl NB; Goffin J; Khomani A; Gupta A; Addison CL; Bane A; Seely J; Filion ML; Pond GR; Levine MN
    Lung Cancer; 2017 Feb; 104():65-69. PubMed ID: 28213002
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
    Calabrò L; Morra A; Fonsatti E; Cutaia O; Amato G; Giannarelli D; Di Giacomo AM; Danielli R; Altomonte M; Mutti L; Maio M
    Lancet Oncol; 2013 Oct; 14(11):1104-1111. PubMed ID: 24035405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thoracic stop-flow perfusion in the treatment of refractory malignant pleural mesothelioma: a phase I-II evaluation/trial.
    Guadagni S; Clementi M; Valenti M; Fiorentini G; Cantore M; Kanavos E; Amicucci G
    In Vivo; 2006; 20(6A):715-8. PubMed ID: 17203752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SU6668, a multiple tyrosine kinase inhibitor, inhibits progression of human malignant pleural mesothelioma in an orthotopic model.
    Van TT; Hanibuchi M; Goto H; Kuramoto T; Yukishige S; Kakiuchi S; Sato S; Sakaguchi S; Dat le T; Nishioka Y; Akiyama S; Sone S
    Respirology; 2012 Aug; 17(6):984-90. PubMed ID: 22574723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II clinical trial of the vascular disrupting agent BNC105P as second line chemotherapy for advanced Malignant Pleural Mesothelioma.
    Nowak AK; Brown C; Millward MJ; Creaney J; Byrne MJ; Hughes B; Kremmidiotis G; Bibby DC; Leske AF; Mitchell PLR; Pavlakis N; Boyer M; Stockler MR
    Lung Cancer; 2013 Sep; 81(3):422-427. PubMed ID: 23787063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pemetrexed alone or in combination with cisplatin in previously treated malignant pleural mesothelioma: outcomes from a phase IIIB expanded access program.
    Jänne PA; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Ye Z; Monberg MJ; Obasaju CK;
    J Thorac Oncol; 2006 Jul; 1(6):506-12. PubMed ID: 17409909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    Saltz LB; Rosen LS; Marshall JL; Belt RJ; Hurwitz HI; Eckhardt SG; Bergsland EK; Haller DG; Lockhart AC; Rocha Lima CM; Huang X; DePrimo SE; Chow-Maneval E; Chao RC; Lenz HJ
    J Clin Oncol; 2007 Oct; 25(30):4793-9. PubMed ID: 17947727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of cediranib in patients with malignant pleural mesothelioma: SWOG S0509.
    Garland LL; Chansky K; Wozniak AJ; Tsao AS; Gadgeel SM; Verschraegen CF; Dasilva MA; Redman M; Gandara DR
    J Thorac Oncol; 2011 Nov; 6(11):1938-45. PubMed ID: 21964533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Single-agent pemetrexed for chemonaïve and pretreated patients with malignant pleural mesothelioma: results of an International Expanded Access Program.
    Taylor P; Castagneto B; Dark G; Marangolo M; Scagliotti GV; van Klaveren RJ; Labianca R; Serke M; Schuette W; van Meerbeeck JP; Heigener D; Liu Y; Adachi S; Blatter J; von Pawel J
    J Thorac Oncol; 2008 Jul; 3(7):764-71. PubMed ID: 18594323
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase II trial of single oral FGF inhibitor, AZD4547, as second or third line therapy in malignant pleural mesothelioma.
    Lam WS; Creaney J; Chen FK; Chin WL; Muruganandan S; Arunachalam S; Attia MS; Read C; Murray K; Millward M; Spiro J; Chakera A; Gary Lee YC; Nowak AK
    Lung Cancer; 2020 Feb; 140():87-92. PubMed ID: 31901768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Prognosis related clinical and molecular factors in malignant pleural mesothelioma].
    Wang YY; Zhang H; Bai H; Wang SH; Wu MN; An TT; Zhao J; Zhuo ML; Duan JC; Wang ZJ; Wang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Mar; 36(3):162-8. PubMed ID: 23856136
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SWOG S0722: phase II study of mTOR inhibitor everolimus (RAD001) in advanced malignant pleural mesothelioma (MPM).
    Ou SH; Moon J; Garland LL; Mack PC; Testa JR; Tsao AS; Wozniak AJ; Gandara DR
    J Thorac Oncol; 2015 Feb; 10(2):387-91. PubMed ID: 25611229
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dihydro-5-azacytidine and cisplatin in the treatment of malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Samuels BL; Herndon JE; Harmon DC; Carey R; Aisner J; Corson JM; Suzuki Y; Green MR; Vogelzang NJ
    Cancer; 1998 Apr; 82(8):1578-84. PubMed ID: 9554537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma.
    Gregorc V; Zucali PA; Santoro A; Ceresoli GL; Citterio G; De Pas TM; Zilembo N; De Vincenzo F; Simonelli M; Rossoni G; Spreafico A; Grazia Viganò M; Fontana F; De Braud FG; Bajetta E; Caligaris-Cappio F; Bruzzi P; Lambiase A; Bordignon C
    J Clin Oncol; 2010 May; 28(15):2604-11. PubMed ID: 20406925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
    Jassem J; Ramlau R; Santoro A; Schuette W; Chemaissani A; Hong S; Blatter J; Adachi S; Hanauske A; Manegold C
    J Clin Oncol; 2008 Apr; 26(10):1698-704. PubMed ID: 18375898
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
    Garland LL; Rankin C; Gandara DR; Rivkin SE; Scott KM; Nagle RB; Klein-Szanto AJ; Testa JR; Altomare DA; Borden EC
    J Clin Oncol; 2007 Jun; 25(17):2406-13. PubMed ID: 17557954
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Life after first-line chemotherapy in malignant pleural mesothelioma: a North-East England experience.
    Steer J; Bough G; Razak AR; Meachery GJ; Hughes A
    Clin Oncol (R Coll Radiol); 2010 Apr; 22(3):231-5. PubMed ID: 20346340
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pemetrexed maintenance therapy in patients with malignant pleural mesothelioma.
    van den Bogaert DP; Pouw EM; van Wijhe G; Vernhout RM; Surmont VF; Hoogsteden HC; van Klaveren RJ
    J Thorac Oncol; 2006 Jan; 1(1):25-30. PubMed ID: 17409823
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.